YANG JI CHEMICAL CO., LTD.

Patent Applications and Registrations

Patent applications and USPTO patent grants for YANG JI CHEMICAL CO., LTD..The latest application filed is for "composite liquid pharmaceutical composition comprising crude drug-stabilizing dried powder".

Company Profile

2.6.8

YANG JI CHEMICAL CO., LTD. - Suwon-si Gyeonggi-do KR
YANG JI CHEMICAL CO., LTD. - Suwon-si, Gyeonggi-do KR
YANG JI CHEMICAL CO., LTD. - Ansan KR
Yang Ji Chemical Co., Ltd. - KR KR
Yang Ji Chemical Company Ltd. - 638-6 Sunggak-dong Anson, Kunggi-do KR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Janus kinase 1 selective inhibitor and pharmaceutical use thereof Grant 10,407,430 - Chough , et al. Sept	2019-09-10
Composite Liquid Pharmaceutical Composition Comprising Crude Drug-stabilizing Dried Powder App 20190015325 - KIM; Kyoung Rak ; et al.	2019-01-17
Substituted N-(pyrrolidine-3-yl)-7H-pyrrolo[2,3-D]pyrimidine-4-amine as janus kinase inhibitor Grant 10,081,635 - Kim , et al. September 25, 2	2018-09-25
Janus Kinase 1 Selective Inhibitor And Pharmaceutical Use Thereof App 20180237440 - CHOUGH; Chieyeon ; et al.	2018-08-23
Substituted N-(pyrrolidine-3-yl)-7h-pyrrolo[2,3-d]pyrimidine-4-amine As Janus Kinase Inhibitor App 20170283421 - Kim; Jong Hoon ; et al.	2017-10-05
Method For Preventing And Treating Thrombotic Disorders Using A Pharmaceutical Composition Comprising An Extract Of Lindera Obtusiloba App 20140255529 - OAK; Min-Ho ; et al.	2014-09-11
Composition comprising the extracts of lindera obtusiloba for prevention and treatment of cardiovascular diseases Grant 8,734,866 - Oak , et al. May 27, 2	2014-05-27
Piperazinyl 3-aminopyrrolidine derivatives as a CCR2 antagonists Grant 8,575,173 - Lim , et al. November 5, 2	2013-11-05
Piperazinyl 3-aminopyrrolidine Derivatives As A Ccr2 Antagonist App 20120190689 - Lim; Jee Woong ; et al.	2012-07-26
Composition Comprising The Extracts Of Lindera Obtusiloba For Prevention And Treatment Of Cardiovascular Diseases App 20110045111 - Oak; Min-Ho ; et al.	2011-02-24
Novel inhibitor compounds specific of secreted non-pancreatic human a<sb>2</sb>phospholipase of group II App 20050075345 - Heymans, Francoise ; et al.	2005-04-07

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.